Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Imaging
Published in: Cancer Imaging 1/2015

Open Access 01-12-2015 | Research article

Prognostic significance of 18FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis

Authors: Qian Xia, Jianjun Liu, Cheng Wu, Shaoli Song, Linjun Tong, Gang Huang, Yuanbo Feng, Yansheng Jiang, Yewei Liu, Ting Yin, Yicheng Ni

Published in: Cancer Imaging | Issue 1/2015

Login to get access

Abstract

Background

The role of 18-fluorodeoxyglucose positron emission tomography CT (18FDG PET/CT), as a prognostic factor for survival in colorectal cancer patients with liver metastases, is still controversial. We sought to perform a meta-analysis of the literature to address this issue.

Methods

A systematic literature search was performed to identify the studies that associated 18FDG PET/CT to clinical survival outcomes of patients with liver metastases. Methodological qualities of the included studies were also assessed. The summarized hazard ratio (HR) was estimated by using fixed- or random-effect model according to heterogeneity between trails.

Results

By analyzing a total of 867 patients from 15 studies, we found that PET/CT for metabolic response to the therapy was capable of predicting event-free survival (EFS) and overall survival (OS) with statistical significance, and the HR was 0.45 (95 % confidence interval [CI], 0.26–0.78) and 0.36 (95 % CI, 0.18–0.71), respectively. Furthermore, pre-treatment 18FDG PET/CT with high standardized uptake value (SUV) was also significantly associated with poorer OS HR, 1.24; (95 % CI, 1.06–1.45). However, we did not find a statistically significant effect of post-treatment SUV for predicting OS HR, 1.68; (95 % CI, 0.63–4.52).

Conclusions

The present meta-analysis confirms that 18FDG PET/CT is a useful tool to help predict survival outcomes in patients with liver metastases.
Appendix
Available only for authorised users
Literature
1.
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.PubMedCentralCrossRefPubMed
2.
Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229(2):526–33.CrossRefPubMed
3.
de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008;19:348–52.CrossRefPubMed
4.
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.CrossRefPubMed
5.
Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–65.PubMed
6.
Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43:1018–27.PubMed
7.
Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–8.CrossRefPubMed
8.
Saini S. Radiologic measurement of tumor size in clinical trials: past, present, and future. Am J Roentgenol. 2001;176:333–4.CrossRef
9.
Van den Abbeele AD. The lessons of GIST – PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13 Suppl 2:8–13.CrossRefPubMed
10.
Aras M, Erdil TY, Dane F, Gungor S, Ones T, Dede F, et al. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med Commun. 2015 Oct 5. [Epub ahead of print].
11.
Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255–60.CrossRefPubMed
12.
Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18 F]-D-glucose. Cancer. 1998;82:2227–34.CrossRefPubMed
13.
Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907–11.PubMed
14.
Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, et al. 18 F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med. 2012;53:371–7.CrossRefPubMed
15.
Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, et al. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J Nucl Med. 2013;54:2062–9.CrossRefPubMed
16.
Zhao Q, Feng Y, Mao X, Qie M. Prognostic Value of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography or PET-Computed Tomography in Cervical Cancer. Int J Gynecol Cancer. 2013;23:1184–90.CrossRefPubMed
17.
Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in Non-small Cell Lung Cancer (NSCLC). J Tho Rac Oncol. 2008;3:6–12.CrossRef
18.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMed
19.
Wang Y, Zeng T. Practical methods for incorporating summary time-to event data into meta-analysis. Trials. 2013;19:391.CrossRef
20.
21.
Small RM, Lubezky N, Shmueli E, Figer A, Aderka D, Nakache R, et al. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol. 2009;1(99):93–8.CrossRef
22.
De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, et al. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer. 2012;106:1926–33.PubMedCentralCrossRefPubMed
23.
Mertens J, De Bruyne S, Van Damme N, Smeets P, Ceelen W, Troisi R, et al. Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2013;40:1214–22.CrossRefPubMed
24.
Lee HS, Kim HO, Hong YS, Kim TW, Kim JC, Yu CS, et al. Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery. J Nucl Med. 2014;55:582–9.CrossRefPubMed
25.
Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18 F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771–5.CrossRefPubMed
26.
Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2012;23:1687–93.CrossRefPubMed
27.
Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, et al. The role of early 18 F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumor density criteria. Eur J Nucl Med Mol Imaging. 2012;39:1391–9.CrossRefPubMed
28.
Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, et al. Validation of Several SUV-Based Parameters Derived from 18 F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer. J Nucl Med. 2013;54:1202–8.CrossRefPubMed
29.
Muralidharan V, Kwok M, Lee ST, Lau L, Scott AM, Christophi C, et al. Prognostic Ability of 18 F-FDG PET/CT in the Assessment of Colorectal Liver Metastases. J Nucl Med. 2012;53:1345–51.CrossRefPubMed
30.
Zalom M, Yu R, Friedman M, Bresee C, Waxman A. FDG PET/CT as a Prognostic Test After 90Y Radioembolization in Patients With Metastatic Hepatic Disease. Clin Nucl Med. 2012;37:862–5.CrossRefPubMed
31.
Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.CrossRefPubMed
32.
Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300–9.PubMedCentralCrossRefPubMed
33.
Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700–8.PubMed
34.
Lau LF, Williams DS, Lee ST, Scott AM, Christophi C, Muralidharan V. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. Ann Surg Oncol. 2014;21:2420–8.CrossRefPubMed
35.
de Geus-Oei LF, Wiering B, Krabbe PF, Ruers TJ, Punt CJ, Oyen WJ. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol. 2006;17:1650–5.CrossRefPubMed
36.
Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:3945.
37.
Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on 18F-fluoro-2- deoxy-glucose-positron emission tomography scan in non-small cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201–6.PubMed
38.
Tam HH, Cook GJ, Chau I, Drake B, Zerizer I, Du Y, et al. The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis. Clin Nucl Med. 2015;40:259–64.CrossRef
39.
Sabet A, Meyer C, Aouf A, Sabet A, Ghamari S, Pieper CC, et al. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging. 2015;42:370–6.CrossRefPubMed
Metadata
Title
Prognostic significance of 18FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis
Authors
Qian Xia
Jianjun Liu
Cheng Wu
Shaoli Song
Linjun Tong
Gang Huang
Yuanbo Feng
Yansheng Jiang
Yewei Liu
Ting Yin
Yicheng Ni
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2015
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-015-0055-z

Other articles of this Issue 1/2015

Cancer Imaging 1/2015 Go to the issue

Research article

Relevance of computerized tomography in the preoperative evaluation of patients with vulvar cancer: a prospective study

Research article

The presurgical T staging of non-small cell lung cancer: efficacy comparison of 64-MDCT and 3.0 T MRI

Research article

C-arm computed tomography parenchymal blood volume measurement in evaluation of hepatocellular carcinoma before transarterial chemoembolization with drug eluting beads

Research article

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy

Research article

Primary hepatic neuroendocrine tumors: comparing CT and MRI features with pathology

Research article

Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits